Podium to Practice: EHA 2026 – Multiple Myeloma: MAJESTEC-3
OR
Studies / Trials Discussed
S198 – TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
S198 – TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK
Abstract of the paper or summary description of the presentation:
LB5008 – TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.